For the Inventor, By the Inventor

Enter inventor name

San Diego, CA, United States of America

Robin M Jackman

USPTO Granted Patents = 15 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 3.9

ph-index = 6

Forward Citations = 87(Granted Patents)

Company Filing History:

Biomarin Pharmaceutical Inc.

Leading Biosciences, Inc.

January Therapeutics, Inc.

Zacharon Pharmaceuticals, Inc.

Years Active: 2012-2022

Loading Chart...

Loading Chart...

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11306399 - Nanoparticle compositions (2022-04-19),

2. 11306111 - Organophosphate derivatives (2022-04-19),

3. 11123317 - Compositions for the treatment of autodigestion (2021-09-21),

4. 10793894 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2020-10-06),

5. 10677786 - Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2020-06-09),

6. 10260084 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2019-04-16),

7. 9915649 - Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA (2018-03-13),

8. 9775821 - Compositions for the treatment of autodigestion (2017-10-03),

9. 9677116 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2017-06-13),

10. 9340822 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2016-05-17),

11. 9314442 - Compositions for the treatment of autodigestion (2016-04-19),

12. 9222120 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2015-12-29),

13. 8809009 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2014-08-19),

14. 8771974 - Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder (2014-07-08),

15. 8232073 - Quantification of non-reducing end glycan residual compounds (2012-07-31),

Title: Innovator Spotlight: Robin M Jackman

Introduction

Robin M Jackman is a distinguished inventor based in San Diego, CA. With an impressive portfolio of 15 patents, he has significantly contributed to the field of pharmaceuticals and biotechnology. His work primarily revolves around innovative compounds and compositions that aim to address various health challenges.

Latest Patents

Two of his latest patents showcase his expertise in organophosphate derivatives and nanoparticle compositions. The first patent details organophosphates and pharmaceutical compositions comprising these compounds, potentially offering new avenues for treatments. The second patent focuses on nanoparticle compositions that include an organophosphate compound along with pharmaceutically acceptable carriers, highlighting Jackman’s commitment to advancing pharmaceutical technologies.

Career Highlights

Throughout his career, Robin has worked with notable companies such as BioMarin Pharmaceutical Inc. and Leading Biosciences, Inc. His roles in these organizations have allowed him to hone his skills and drive innovation in the pharmaceutical industry.

Collaborations

Jackman's collaborative spirit is evident through his work with colleagues such as Brett E Crawford and Charles A Glass. Together, they have contributed to the development of groundbreaking research and inventions that enhance therapeutic options.

Conclusion

Robin M Jackman exemplifies the essence of innovation in the biotechnology field. His extensive patent portfolio and commitment to improving pharmaceuticals highlight the impact of his work. As he continues to explore new frontiers, the scientific community eagerly anticipates his future contributions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…